Valeant Pharmaceuticals Appoints Michael Karin, Ph.D. to Scientific Advisory Board.

COSTA MESA, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) announced today that it has appointed Michael Karin, Ph.D. to its Scientific Advisory Board. Dr. Karin joins current members, Francis V. Chisari, M.D., David D. Ho, M.D., James E. Niedel, M.D., Ph.D. and Roberts A. Smith, Ph.D.

"We are honored to have Dr. Karin join our advisory board and look forward to his insight and knowledge as we progress our discovery and development opportunities," Timothy C. Tyson, Valeant's President and Chief Executive Officer, said. "Dr. Karin was recently elected a member of the prestigious National Academy of Sciences by his peers for the quality and depth of his research in the scientific community."

Dr. Karin is the Professor of Pharmacology at the University of California, San Diego. He has published more than 320 papers and was ranked 12th among the world's most cited scientists in Science Watch, 2003. In 1993, Dr. Karin co-founded Signal Pharmaceuticals and in May 2005 was elected a member of the U.S. National Academy of Sciences. Dr. Karin made seminal contributions to the discipline of cellular signal transduction pathways and is a world authority on NF-kB signaling due to his discovery of the upstream IkB kinase (IKK).

Valeant's scientific advisory board was formed in early 2004 to provide independent expert opinion on research and development programs, assist in drug discovery activities, and identify opportunities to enhance research and development productivity within the organization.

About Valeant

Valeant Pharmaceuticals International (NYSE:VRX) is a global, publicly traded, research-based specialty pharmaceutical company that discovers, develops, manufactures and markets pharmaceutical products primarily in the areas of neurology, infectious disease and dermatology. More information about Valeant can be found at www.valeant.com.